Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Imaging Probes in Idiopathic Pulmonary Fibrosis
NCT04362644Phase 1Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Dec 2020
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DPA-714 and fludeoxyglucose f 18 in idiopathic pulmonary fibrosis (IPF), sponsored by University of Alabama at Birmingham. Primary endpoint: Correlation of quantitative PET measures of lung inflammation with [F-18]FDG and [F-18]DPA-714 to pulmonary function tests. Started Dec 2020; status: recruiting.
02
Drugs
DPA-714fludeoxyglucose f 18
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04362644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04362644.